KT
TCRT icon

Kanaly Trust’s Alaunos Therapeutics TCRT Stock Holding History

Kanaly Trust’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$7K Hold
9
– – ﹤0.01% 612
2016
Q3 		$8K Hold
9
– – ﹤0.01% 579
2016
Q2 		$7K Hold
9
– – ﹤0.01% 604
2016
Q1 		$10K Hold
9
– – ﹤0.01% 551
2015
Q4 		$11K Hold
9
– – ﹤0.01% 549
2015
Q3 		$12K Buy
+9
New +$14.9K ﹤0.01% 522
2015
Q2 		– Hold
0
– – – 862

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kanaly Trust's TCRT Position: Q4 2016 in Review

Kanaly Trust held its Alaunos Therapeutics (TCRT) position steady in Q4 2016 at 9 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #612.

Kanaly Trust first reported a position in TCRT in Q3 2015 and has held it in 6 quarters since. The position peaked at $12K in Q3 2015. 136 funds tracked by Wall St. Rank hold TCRT as of Q4 2016.

  • Kanaly Trust held 9 shares of Alaunos Therapeutics worth $7K as of Q4 2016.
  • Kanaly Trust left its Alaunos Therapeutics share count unchanged in Q4 2016.
  • Alaunos Therapeutics made up ﹤0.01% of Kanaly Trust's portfolio in Q4 2016, its #612 holding.
  • Kanaly Trust first reported a position in Alaunos Therapeutics in Q3 2015 and has held it in 6 quarters since.
  • Kanaly Trust's Alaunos Therapeutics position peaked at $12K in Q3 2015.
  • 136 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2016.

Based on Kanaly Trust's 13F filing for Q4 2016, filed 23 Jan 2017.